JP7475731B2 - カンナビノイドプロドラッグ化合物 - Google Patents

カンナビノイドプロドラッグ化合物 Download PDF

Info

Publication number
JP7475731B2
JP7475731B2 JP2022519475A JP2022519475A JP7475731B2 JP 7475731 B2 JP7475731 B2 JP 7475731B2 JP 2022519475 A JP2022519475 A JP 2022519475A JP 2022519475 A JP2022519475 A JP 2022519475A JP 7475731 B2 JP7475731 B2 JP 7475731B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
cancer
group
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022519475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549502A (ja
Inventor
ジョン，キーラン
Original Assignee
ファーストライト ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーストライト ファーマシューティカルズ，エルエルシー filed Critical ファーストライト ファーマシューティカルズ，エルエルシー
Publication of JP2022549502A publication Critical patent/JP2022549502A/ja
Priority to JP2024063204A priority Critical patent/JP2024088768A/ja
Application granted granted Critical
Publication of JP7475731B2 publication Critical patent/JP7475731B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/50—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/54—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2022519475A 2019-09-26 2020-09-25 カンナビノイドプロドラッグ化合物 Active JP7475731B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063204A JP2024088768A (ja) 2019-09-26 2024-04-10 カンナビノイドプロドラッグ化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906228P 2019-09-26 2019-09-26
US62/906,228 2019-09-26
PCT/US2020/052829 WO2021062231A2 (en) 2019-09-26 2020-09-25 Cannabinoid prodrug compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063204A Division JP2024088768A (ja) 2019-09-26 2024-04-10 カンナビノイドプロドラッグ化合物

Publications (2)

Publication Number Publication Date
JP2022549502A JP2022549502A (ja) 2022-11-25
JP7475731B2 true JP7475731B2 (ja) 2024-04-30

Family

ID=75166839

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519475A Active JP7475731B2 (ja) 2019-09-26 2020-09-25 カンナビノイドプロドラッグ化合物
JP2024063204A Pending JP2024088768A (ja) 2019-09-26 2024-04-10 カンナビノイドプロドラッグ化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063204A Pending JP2024088768A (ja) 2019-09-26 2024-04-10 カンナビノイドプロドラッグ化合物

Country Status (5)

Country Link
US (2) US11980602B2 (enExample)
EP (1) EP4034100A4 (enExample)
JP (2) JP7475731B2 (enExample)
CA (1) CA3152168A1 (enExample)
WO (1) WO2021062231A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022111587A1 (zh) * 2020-11-25 2022-06-02 成都百裕制药股份有限公司 大麻素类化合物的制备方法
CN115315418B (zh) * 2021-04-06 2023-03-21 山东绿叶制药有限公司 大麻二酚前药及其药物组合物和应用
CN116253671B (zh) * 2021-12-10 2025-07-04 德义制药有限公司 一种大麻二酚衍生物及其制备方法和应用
EP4531836A1 (en) * 2022-05-31 2025-04-09 Trait Biosciences, Inc. Water-soluble cannabinoid prodrugs compositions and methods of synthesizing the same
CN120531715A (zh) * 2025-05-28 2025-08-26 中国人民解放军军事科学院军事医学研究院 大麻二酚在寡肽转运体抑制剂中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008107879A1 (en) 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel cannabidiol derivatives and their use as anti-inflammatory agents
WO2009018389A1 (en) 2007-07-30 2009-02-05 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
WO2018091551A1 (en) 2016-11-15 2018-05-24 Full Spectrum Laboratories Ltd Bio-stable cannabinoid compounds and methods for enhancing their physiological concentration
JP2022535238A (ja) 2019-06-06 2022-08-05 アプライド マテリアルズ インコーポレイテッド 撮像システム及び合成画像を生成する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ745595A (en) * 2016-01-29 2019-12-20 Univ Mississippi Biologically active cannabidiol analogs
EP3442953A1 (en) * 2016-04-15 2019-02-20 Teewinot Technologies Limited Biosynthesis of cannabinoid prodrugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008107879A1 (en) 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel cannabidiol derivatives and their use as anti-inflammatory agents
WO2009018389A1 (en) 2007-07-30 2009-02-05 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
WO2018091551A1 (en) 2016-11-15 2018-05-24 Full Spectrum Laboratories Ltd Bio-stable cannabinoid compounds and methods for enhancing their physiological concentration
JP2022535238A (ja) 2019-06-06 2022-08-05 アプライド マテリアルズ インコーポレイテッド 撮像システム及び合成画像を生成する方法

Also Published As

Publication number Publication date
WO2021062231A3 (en) 2021-05-06
US11980602B2 (en) 2024-05-14
JP2024088768A (ja) 2024-07-02
US20220211656A1 (en) 2022-07-07
JP2022549502A (ja) 2022-11-25
US20240408046A1 (en) 2024-12-12
CA3152168A1 (en) 2021-04-01
WO2021062231A2 (en) 2021-04-01
EP4034100A4 (en) 2023-10-11
EP4034100A2 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
JP7475731B2 (ja) カンナビノイドプロドラッグ化合物
US10092547B2 (en) Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero- heteraphanes and metallocenes useful for treating HCV infections
KR102666477B1 (ko) 글루타민 유사체의 프로드럭
CN101340947B (zh) Iap-抑制剂和紫杉烷7的组合
TW201620554A (zh) 抗ｈｅｒ２抗體－藥物結合物
WO2021022163A2 (en) Compounds and uses thereof
KR20100038111A (ko) 디펩토이드 전구약물 및 그의 용도
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
WO2008127659A2 (en) Combination therapy for cancer
JP2016026142A (ja) ニューロトロフィン・ミメティック及びその使用
TWI399206B (zh) 抗腫瘤劑
EP4433095A1 (en) Peptide conjugates of peptidic tubulin inhibitors as therapeutics
TW202313559A (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
ES2982346T3 (es) Sales metálicas y usos de las mismas
WO2007023778A1 (ja) 新規抗癌併用薬
US6977241B2 (en) SH2 domain binding inhibitors
CN109796519A (zh) 一类甾体化合物及其应用
CA3224123A1 (en) Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
CN116322780A (zh) 化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240410

R150 Certificate of patent or registration of utility model

Ref document number: 7475731

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150